Future Role for Selective Phospholipase A₂ Inhibitors in the Prevention of Atherosclerotic Cardiovascular Disease : Phospholipase, inflammation and cardiovascular diseaseROSENSON, Robert S.Cardiovascular drugs and therapy. 2009, Vol 23, Num 1, pp 93-101, issn 0920-3206, 9 p.Article

Low high-density lipoprotein cholesterol and cardiovascular disease : Risk reduction with statin therapyROSENSON, Robert S.The American heart journal. 2006, Vol 151, Num 3, pp 556-563, issn 0002-8703, 8 p.Article

Antiatherothrombotic effects of nicotinic acidROSENSON, Robert S.Atherosclerosis. 2003, Vol 171, Num 1, pp 87-96, issn 0021-9150, 10 p.Article

Low HDL-C : A secondary target of dyslipidemia therapyROSENSON, Robert S.The American journal of medicine. 2005, Vol 118, Num 10, pp 1067-1077, issn 0002-9343, 11 p.Article

Current overview of statin-induced myopathyROSENSON, Robert S.The American journal of medicine. 2004, Vol 116, Num 6, pp 408-416, issn 0002-9343, 9 p.Article

Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilitiesROSENSON, Robert S.Atherosclerosis. 2004, Vol 173, Num 1, pp 1-12, issn 0021-9150, 12 p.Article

Modulating atherosclerosis through inhibition or blockade of angiotensinROSENSON, Robert S.Clinical cardiology (Mahwah, NJ). 2003, Vol 26, Num 7, pp 305-311, issn 0160-9289, 7 p.Article

Functional Assessment of HDL: Moving Beyond Static Measures for Risk AssessmentROSENSON, Robert S.Cardiovascular drugs and therapy. 2010, Vol 24, Num 1, pp 71-75, issn 0920-3206, 5 p.Article

Management of non-high-density lipoprotein abnormalitiesROSENSON, Robert S.Atherosclerosis. 2009, Vol 207, Num 2, pp 328-335, issn 0021-9150, 8 p.Article

Treatment of Hypertension in Metabolic Syndrome Subjects with Amlodipine and Olmesartan―Effects on Oxidized Non-Esterified Free Fatty Acids and Cytokine ProductionROSENSON, Robert S.Cardiovascular drugs and therapy. 2009, Vol 23, Num 4, pp 289-294, issn 0920-3206, 6 p.Article

Colesevelam HCL reduces LDL particle number and increases LDL size in hypercholesterolemiaROSENSON, Robert S.Atherosclerosis. 2006, Vol 185, Num 2, pp 327-330, issn 0021-9150, 4 p.Article

Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome: A randomized, double-blind, controlled studyROSENSON, Robert S; OTVOS, James D; HSIA, Judith et al.Diabetes care. 2009, Vol 32, Num 6, pp 1087-1091, issn 0149-5992, 5 p.Article

Hypertriglyceridemia is associated with an elevated blood viscosity Rosenson: triglycerides and blood viscosityROSENSON, Robert S; SHOTT, Susan; TANGNEY, Christine C et al.Atherosclerosis. 2002, Vol 161, Num 2, pp 433-439, issn 0021-9150Article

The rationale for combination therapyROSENSON, Robert S.The American journal of cardiology. 2002, Vol 90, Num 10B, pp 2K-7K, issn 0002-9149Conference Paper

Elevated Blood viscosity in systemic Lupus erythematosusROSENSON, Robert S; SHOTT, Susan; KATZ, Robert et al.Seminars in arthritis and rheumatism. 2001, Vol 31, Num 1, pp 52-57, issn 0049-0172Article

Systematic Review: Evaluating the Effect of Lipid-Lowering Therapy on Lipoprotein and Lipid ValuesROSENSON, Robert S; UNDERBERG, James A.Cardiovascular drugs and therapy. 2013, Vol 27, Num 5, pp 465-479, issn 0920-3206, 15 p.Article

Phosphotipase A₂ enzymes and the risk of atherosclerosisROSENSON, Robert S; HURT-CAMEJO, Eva.European heart journal. 2012, Vol 33, Num 23, pp 2899-2909, issn 0195-668X, 11 p.Article

Lipoprotein Associated Phospholipase A₂ Inhibition Reduces Generation of Oxidized Fatty Acids Lp-LPA₂ Reduces Oxidized Fatty AcidsROSENSON, Robert S; VRACAR-GRABAR, Marina; HELENOWSKI, Irene et al.Cardiovascular drugs and therapy. 2008, Vol 22, Num 1, pp 55-58, issn 0920-3206, 4 p.Article

Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual riskROSENSON, Robert S; DAVIDSON, Michael H; POURFARZIB, Ray et al.Atherosclerosis. 2010, Vol 213, Num 1, pp 1-7, issn 0021-9150, 7 p.Article

Physicians' interpretation of class effects: A need for thoughtful re-evaluationKENNEDY, Harold L; ROSENSON, Robert S.Journal of the American College of Cardiology. 2002, Vol 40, Num 1, pp 19-26, issn 0735-1097Article

Treating Mixed Hyperlipidemia and the Atherogenic Lipid Phenotype for Prevention of Cardiovascular EventsRUBENFIRE, Melvyn; BROOK, Robert D; ROSENSON, Robert S et al.The American journal of medicine. 2010, Vol 123, Num 10, pp 892-898, issn 0002-9343, 7 p.Article

Results of two clinical trials on the safety and efficacy of Pravastatin 80 and 160 mg per dayROSENSON, Robert S; BAYS, Harold E.The American journal of cardiology. 2003, Vol 91, Num 7, pp 878-881, issn 0002-9149, 4 p.Article

Hyperinsulinemia and Homeostasis Model Assessment of Insulin Resistance as Predictors of Hypertension: A 5-Year Follow-Up Study of Korean SampleSUNG, Ki-Chul; LIM, Soo; ROSENSON, Robert S et al.American journal of hypertension. 2011, Vol 24, Num 9, pp 1041-1045, issn 0895-7061, 5 p.Article

Assessing risk across the spectrum of patients with the metabolic syndromeROSENSON, Robert S.The American journal of cardiology. 2005, Vol 96, Num 4, pp 8E-10E, issn 0002-9149, SUPConference Paper

Modulating peroxisome proliferator―activated receptors for therapeutic benefit? Biology, clinical experience, and future prospectsROSENSON, Robert S; WRIGHT, R. Scott; FARKOUH, Michael et al.The American heart journal. 2012, Vol 164, Num 5, pp 672-680, issn 0002-8703, 9 p.Article